China's INREEDI re-raises tens of millions of yuan for eye-area RF device
What's the deal? Shanghai-based INREEDIDealroom has a profile for this one. Try Dealroom → has closed a Pre-A+ round of tens of millions of yuan, backed by two Taicang-linked funds — the Taicang Loudong Fund and the Taicang Beauty Industry Fund. The company develops radiofrequency (RF) technology for anti-ageing and skin treatment, and will use the proceeds to build an RF factory in Taicang and commercialise its core product.
Why now? The raise lands months after China's stricter Class III registration regime for aesthetic RF devices took effect in April 2026. That shift raises the value of approved products while increasing the cost of clinical development and compliant manufacturing.
A quick re-raise: This is at least INREEDI's second "tens of millions" financing in roughly a year. It closed a Pre-A round in 2025, backed by Yuanhe HoldingsDealroom has a profile for this one. Try Dealroom → and Hongrun, before this follow-on.
What's the endgame? INREEDI's lead product, the BeaShape RF device, is what it calls the first domestically approved Class III RF device for periorbital anti-ageing. Funds will also support later clinical research, post-treatment care products, and a broader "whole-domain anti-ageing" lineup spanning face, body, and scalp.
The company cites clinical data from Shanghai Ninth People's Hospital: after a first treatment, wrinkle scores fell by an average of 1.8 points, and a 12-month follow-up showed a 100% efficacy rate by its measure. It reports an average pain score of 0.15 on a 10-point scale, requiring no anaesthetic.
What they said: "BeaShape obtaining a Class III medical device registration is an important milestone in the company's technology development and clinical translation," an INREEDI representative said (translated from Chinese). "After this round, we will continue to increase investment in core technology and clinical research."
What could go wrong? Competitors are building out their own approved RF product lines, and established aesthetics players have moved into energy-based devices. INREEDI must turn a specialised approval into sustained clinic adoption and scale production in a tighter, more crowded market.
The signal: The round's significance lies less in its undisclosed size than in what it represents — a domestic developer trying to convert a narrow regulatory edge into commercial scale, as China's medical aesthetics sector moves toward higher-barrier, approval-driven products.
Read more: itjuzi.com
Image credit: Generated with Gemini
